| Host: | CHO cells |
| Note: | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | Recombinant-2019 nCoV/COVID19 RBD-protein was developed from cho cells. For use in research applications. |
| Conjugation: | Biotin |
| Formulation: | Lyophilised from 0.2 µm filtered PBS pH 7.4. |
| Dilution Range: | Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: | The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: | The activity was determined by immobilized human ACE2 Protein binding with biotinylated RBD in a functional ELISA assay, the linear was determined to be 10-100 ng/ml NA |
| Immunogen Region: | 319-514 aa |
| Immunogen: | DNA sequence encoding the COVID-19 spike RBD protein domain [319-541] accession #6VSB_A including a C-terminal His AVI tag was expressed in CHO Cells. NA |
| Background | Recombinant 2019-nCoV RBD protein is a protein consisting of 250 amino acid residues, due to glycosylation migrates as an approximately 35kDa protein on SDS-PAGE. |
Information sourced from Uniprot.org